- Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage CNBC
- Novo Nordisk Weight-Loss Pill Prescriptions Hit Three Million Since Launch WSJ
- 80% of Wegovy Pill Users Never Took a Weight Loss Drug Before. Does This Number Change the Entire Novo Nordisk Bear Case? Yahoo Finance
- The Wegovy pill is still dominating the GLP-1 pill market MarketWatch
- Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk unveils new data at ADA 2026 PR Newswire
Add Comment